- Home
- CSCI
CSCI
COSCIENS BIOPHARMA INC
as 04-25-2025 4:00pm EST
Stocks
| Founded: | 1990 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | 1996 |
| Target Price: | N/A | AVG Volume (30 days): | 5.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.96 - $11.10 | Next Earning Date: | 04-09-2025 |
| Revenue: | $9,587,000 | Revenue Growth: | 34.22% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest COSCIENS BIOPHARMA INC News
CSCI Breaking Stock News: Dive into CSCI Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer
Simply Wall St.
14 days ago
COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$13.64 loss in FY 2023)
GlobeNewswire
16 days ago
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
GlobeNewswire
24 days ago
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order
Newsfile
a month ago
COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents
GlobeNewswire
a month ago
COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product
GlobeNewswire
4 months ago
COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization
Simply Wall St.
5 months ago
COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023)
Compare CSCI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CSCI COSCIENS BIOPHARMA INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.